NGENF - NervGen Pharma reports Q3 results November, 19 2020 08:37 AM NervGen Pharma Corp NervGen Pharma (NGENF): Q3 GAAP EPS of -$0.06.The net cash burn for Q3 2020 from operating activities was ~$1.2M.Cash balance of $7.7MPress Release For further details see: NervGen Pharma reports Q3 results